Back to search

Netherlands· NL-20729c30f069

Cefepim Fresenius Kabi 2 g, poeder voor oplossing voor injectie of infusie

A cefepime product containing cefepimedihydrochloride 1-water, registered in Netherlands by Fresenius Kabi Nederland B.V.. The same ATC class is registered in 17 of our 19 countries.

ATC J01DE01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedCefepim Fresenius Kabi 2 g, poeder vo…ATCJ01DE01REGISTER NO.NL-20729c30f069PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Cefepime is registered in 17 of 19 countries.

Countries holding a registration under ATC J01DE01 (cefepime), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Cefepime · ATC J01DE01

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cefepime costs, country by country.

Normalised to the WHO defined daily dose (4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cefepime · price per daily dose (4 g)

USD · FX 28 Sept 2026

  • ES Spain$33.20
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
CEFEPIMEDIHYDROCHLORIDE 1-WATER
Manufacturer
Fresenius Kabi Nederland B.V.
Country
Netherlands (NL)
ATC code
J01DE01
ATC class
Cefepime
Defined daily dose
4 g, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    102544

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

189 interactions on record for cefepime.

Graded by severity as the source publishes them — 19 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cefepime · interactions on record

189 records

  • 19 moderate
  • 170 info

Most severe, free to view

  • Sodium picosulfateA06AB08moderate
  • NeomycinA07AA01moderate
  • StreptomycinA07AA04moderate
  • KanamycinA07AA08moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cefepime in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cefepime products

Authorised across Europe · EMA

The same active substance is authorised in 26 EEA countries. Names it is sold under:

  • Austria · Cefepim Aptapharma, Cefepim Mip
  • Belgium · Cefepim Fresenius Kabi, Céfépime Ldp-Laboratorios Torlan
  • Bulgaria · Алфацеф, Бактерипим
  • Cyprus · Cefepim Noridem, Cefepime Aptapharma
  • Czechia · Cefepim Mip, Cefepim Noridem
  • Germany · Cefepim Accord, Cefepim Mip
  • Denmark · Cefepim Mip
  • Estonia · Alphacef, Cefepime Mip
  • Spain · Cefepima Kabi, Cefepima Ldp-Laboratorios Torlan
  • Finland · Cefepim Mip Pharma
  • France · Cefepime Accord, Cefepime Noridem
  • Greece · Anticepim, Cefepime /Kabi
  • Croatia · Cefepim Aptapharma, Cefepime Kabi
  • Hungary · Cefepim Aptapharma, Cefepim Noridem
  • Italy · Cefepime Noridem, Cefepime Qilu
  • Lithuania · Cefepime Mip, Cefepime Norameda
  • Luxembourg · Cefepime Noridem
  • Latvia · Cefepime Mip, Cefepime Norameda
  • Malta · Cefepime Aptapharma
  • Norway · Cefepim Mip
  • Poland · Cefepim Mip Pharma, Cefepime Aptapharma
  • Portugal · Cefepima Accord, Cefepima Basi
  • Romania · Cefepimă Aptapharma, Cefepimă Mip
  • Sweden · Cefepim Mip
  • Slovenia · Cefepim Aptapharma, Cefepim Kabi
  • Slovakia · Cefepim Mip, Cefepím Noridem

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e23f8f1b-55b9-4f35-8e64-996504f85ddc
GET /v1/drugs/e23f8f1b-55b9-4f35-8e64-996504f85ddc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor oplossing voor injectie of infusie",
  "route": "Intraveneus gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h102544_smpc.pdf",
  "strength": null,
  "atc_label": "Cefepime",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg102544",
  "excipients": [
    "ARGININE, (L-)"
  ],
  "substances": [
    "CEFEPIMEDIHYDROCHLORIDE 1-WATER"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h102544.pdf",
  "authorised_at": "2010/08/20",
  "procedure_number": "NL/H/1370/002",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "102544",
  "additional_monitoring": "N"
}

See everything about cefepime.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.